Interestingly, a phase II study (NCT04300140) is planned to assess the safety and efficacy of AVB-S6-500 as monotherapy, or in combination with cabozantinib (a potent RTK inhibitor including AXL), or cabozantinib/nivolumab (anti-PD-1), in patients with advanced and metastatic ccRCC (Table 1). Here, AXL is linked to nonpapillary renal cell carcinoma.